Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation Maura R.V. Ikoma-Colturato; Miriam P. Beltrame; Felipe M. Furtado; Glicinia Pimenta; Elaine Sobral da Costa; Ana Paula Azambuja; Mariester Malvezzi; Mihoko Yamamoto;

All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia Reza Mirfakhraie; Bentolhoda Kuhestani Dehaghi; Mahmoud Dehghani Ghorbi; Haniyeh Ghaffari-Nazari; Mozhdeh Mohammadian; Maryam Salimi; Maria Tavakoli Ardakani; Sayeh Parkhideh;

BLINATUMOMAB BRIDGING THERAPY FOR EFFECTIVE MANAGEMENT OF MRD IN PRO-B ALL WITH CNS INVOLVEMENT: A CASE REPORT OF POST TRANSPLANT PATIENT AT 23 MONTHS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION Ceren Dehri Bah¿i; Birol Güvenç;